It is the short-cut for sure.
FDA dont usually suggest a Ph2b/3 right after Ph1b/2a, given the sample size of RAD101 trial history.
Sometimes they still require a complete Ph2 to test on patient in different doses.
It is the short-cut for sure. FDA dont usually suggest a Ph2b/3...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
-0.001(3.23%) |
Mkt cap ! $65.18M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.1¢ | 3.0¢ | $421.5K | 14.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 949848 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 289676 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| RAD (ASX) Chart |